{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:18:35Z","timestamp":1793121515710,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ibroneuroscience.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.neuroscience.2024.11.022","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T05:28:03Z","timestamp":1731562083000},"page":"222-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP\/PS1\/tau mice"],"prefix":"10.1016","volume":"563","author":[{"given":"Zhao-Jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Na","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Fan","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-3260","authenticated-orcid":false,"given":"Christian","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Na","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2024.11.022_b0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbr.2009.06.035","article-title":"Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer\u2019s disease","volume":"205","author":"Abbas","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2125.2010.03830.x","article-title":"Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?","volume":"71","author":"Akter","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0015","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0020","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijbiomac.2020.11.192","article-title":"Review on Alzheimer's disease: inhibition of amyloid beta and tau tangle formation","volume":"167","author":"Ashrafian","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0025","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0030","doi-asserted-by":"crossref","unstructured":"Batista, A.F., Forny-Germano, L., Clarke, J.R., Lyra, E. Silva N.M., Brito-Moreira, J., Boehnke, S.E., Winterborn, A., Coe, B.C., Lablans, A., Vital, J.F., Marques, S.A., Martinez, A.M., Gralle, M., Holscher, C., Klein, W.L., Houzel, J.C., Ferreira, S.T., Munoz, D.P., De Felice, F.G., 2018. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. J. Pathol, 245, 85\u2013100.","DOI":"10.1002\/path.5056"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0035","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1523\/JNEUROSCI.4814-07.2008","article-title":"Dynamics of the microglial\/amyloid interaction indicate a role in plaque maintenance","volume":"28","author":"Bolmont","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0040","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s42255-021-00344-4","article-title":"Central and peripheral GLP-1 systems independently suppress eating","volume":"3","author":"Brierley","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbr.2016.10.033","article-title":"Lixisenatide attenuates the detrimental effects of amyloid beta protein on spatial working memory and hippocampal neurons in rats","volume":"318","author":"Cai","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0050","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","article-title":"Neuroinflammation in Alzheimer's disease: Current evidence and futuredirections","volume":"12","author":"Calsolaro","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jocn.2020.09.054","article-title":"Semaglutide-mediated protection against Abeta correlated with enhancement of autophagy and inhibition of apotosis","volume":"81","author":"Chang","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0060","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1111\/ejn.15619","article-title":"Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease","volume":"56","author":"Cummings","year":"2022","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0065","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-018-0871-0","article-title":"Semaglutide: first global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179583","article-title":"Anti-Inflammatory effects of GLP-1 receptor activation in the brain in neurodegenerative diseases","volume":"23","author":"Diz-Chaves","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0075","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metab."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1033479","article-title":"The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease","volume":"13","author":"Du","year":"2022","journal-title":"Front Endocrinol (lausanne)"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0090","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0095","first-page":"S9","article-title":"Evaluation of liraglutide in the treatment of Alzheimer's disease","volume":"17","author":"Edison","year":"2022","journal-title":"Alzheimer Dementia"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0100","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/ncomms3030","article-title":"Scara1 deficiency impairs clearance of soluble amyloid-\u03b2 by mononuclear phagocytes and accelerates Alzheimer's-like disease progression","volume":"4","author":"Frenkel","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0105","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejphar.2008.03.025","article-title":"GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid","volume":"587","author":"Gault","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0115","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/glia.22393","article-title":"Development and homeostasis of \u201cresident\u201d myeloid cells: the case of the microglia","volume":"61","author":"Gomez Perdiguero","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13024-020-00391-7","article-title":"Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease","volume":"15","author":"Guo","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0125","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.neurobiolaging.2012.04.009","article-title":"Liraglutide protects against \u00df-amyloid induced impairment of spatial learning and memory in rats","volume":"32","author":"Han","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0130","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/d41586-018-05717-6","article-title":"Alzheimer's disease","volume":"559","author":"Hodson","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0135","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1212\/WNL.0b013e3181b6bb95","article-title":"Systemic inflammation and disease progression in Alzheimer disease","volume":"73","author":"Holmes","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0140","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13543784.2020.1738383","article-title":"Brain insulin resistance: role in neurodegenerative disease and potential for targeting","volume":"29","author":"H\u00f6lscher","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0145","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bph.15508","article-title":"Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders","volume":"179","author":"H\u00f6lscher","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109952","article-title":"Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: a revolution in the making?","volume":"253","author":"Holscher","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0155","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.neures.2006.04.008","article-title":"Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes","volume":"55","author":"Iwai","year":"2006","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0160","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jnc.13736","article-title":"Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells","volume":"139","author":"Jalewa","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0170","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3233\/JAD-230099","article-title":"The anti-amyloid monoclonal antibody lecanemab: 16 cautionary notes","volume":"94","author":"Kepp","year":"2023","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0180","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neuropharm.2017.11.015","article-title":"Glucagon-like peptide-1 (GLP-1) and neurotransmitters signaling in epilepsy: an insight review","volume":"136","author":"Koshal","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0185","doi-asserted-by":"crossref","unstructured":"Kraeuter, A.K., Guest, P.C., Sarnyai, Z., 2019. The Y-maze for assessment of spatial working and reference memory in mice. Methods Mol. Biol. (Clifton, N.J.), 1916: 105-11.","DOI":"10.1007\/978-1-4939-8994-2_10"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0190","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0195","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1007\/s12035-017-0550-2","article-title":"Activation of glucagon-like peptide-1 receptor promotes neuroprotection in experimental autoimmune encephalomyelitis by reducing neuroinflammatory responses","volume":"55","author":"Lee","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0200","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s11596-021-2467-2","article-title":"Type 2 diabetes mellitus easily develops into Alzheimer's disease via hyperglycemia and insulin resistance","volume":"41","author":"Li","year":"2021","journal-title":"Curr. Med. Sci."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0205","doi-asserted-by":"crossref","first-page":"e2231","DOI":"10.1002\/brb3.2231","article-title":"The GLP-1\/GIP dual-receptor agonist DA5-CH inhibits the NF-kappaB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01","volume":"11","author":"Lv","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0210","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/BF00294609","article-title":"Microglia in cerebellar plaques in Alzheimer's disease","volume":"80","author":"Mattiace","year":"1990","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0215","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neuropharm.2014.07.015","article-title":"Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease","volume":"86C","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0220","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0225","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature06616","article-title":"Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease","volume":"451","author":"Meyer-Luehmann","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0230","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1201982","article-title":"Microglia in Alzheimer's disease: pathogenesis, mechanisms, and therapeutic potentials","volume":"15","author":"Miao","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0235","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0240","doi-asserted-by":"crossref","first-page":"16158","DOI":"10.1038\/s41598-017-16488-x","article-title":"Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells","volume":"7","author":"Panagaki","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0245","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0250","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejphar.2012.12.012","article-title":"The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain","volume":"700","author":"Parthsarathy","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411301","article-title":"Potential role of glucagon-like peptide-1 receptor agonists in the treatment of cognitive decline and dementia in diabetes mellitus","volume":"24","author":"Pelle","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0260","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nri2015","article-title":"Systemic infections and inflammation affect chronic neurodegeneration","volume":"7","author":"Perry","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0265","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/1389450043345245","article-title":"A new Alzheimer's disease interventive strategy: GLP-1","volume":"5","author":"Perry","year":"2004","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0270","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1124\/jpet.102.037481","article-title":"Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4","volume":"302","author":"Perry","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0275","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1463-1326.2010.01259.x","article-title":"Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance","volume":"12","author":"Porter","year":"2010","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0280","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/nn.2923","article-title":"Heterogeneity of CNS myeloid cells and their roles in neurodegeneration","volume":"14","author":"Prinz","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0290","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases","volume":"2292461","author":"Rhea","year":"2023","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0295","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF02899034","article-title":"'Role of microglia in plaque formation in senile dementia of the Alzheimer type. An Immunohistochemical Study'","volume":"51","author":"Rozemuller","year":"1986","journal-title":"Virchows Arch B Cell Pathol. Incl. Mol. Pathol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105404","article-title":"Transgenic mouse models of alzheimer's disease: an integrative analysis","volume":"23","author":"Sanchez-Varo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0305","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0310","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jnc.12469","article-title":"Neuroprotective and anti-apoptotic effects of Liraglutide on SH-SY5Y cells exposed to Methylglyoxal stress","volume":"128","author":"Sharma","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0315","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/bph.12518","article-title":"GluN2C\/GluN2D subunit-selective NMDA receptor potentiator CIQ reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice","volume":"171","author":"Suryavanshi","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0320","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101622","article-title":"Glial cells in Alzheimer's disease: from neuropathological changes to therapeutic implications","volume":"78","author":"Uddin","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109716","article-title":"Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R\/SIRT1\/GLUT4 pathway","volume":"240","author":"Wang","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0335","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0340","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/bs.apha.2022.02.005","article-title":"Cardiovascular effects of GLP-1 receptor agonism","volume":"94","author":"Winquist","year":"2022","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107748","article-title":"The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke","volume":"158","author":"Yang","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0350","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.dsx.2018.03.002","article-title":"Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease","volume":"12","author":"Yildirim Simsir","year":"2018","journal-title":"Diabet. Metabol. Syndrome"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0355","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41583-018-0093-1","article-title":"Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases","volume":"20","author":"Yuan","year":"2019","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111529","article-title":"Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer's disease by suppressing NLRP2 activation in astrocytes","volume":"542","author":"Zhang","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0365","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","article-title":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model","volume":"71","author":"Zhang","year":"2018","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuroscience.2024.11.022_b0370","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JPD-181503","article-title":"Semaglutide is neuroprotective and reduces alpha-synuclein levels in the chronic MPTP mouse model of Parkinson's disease","volume":"9","author":"Zhang","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neuroscience.2024.11.022_b0375","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1038\/s41598-019-42286-8","article-title":"Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice","volume":"9","author":"Zhao","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452224006043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452224006043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:34:11Z","timestamp":1734568451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452224006043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":75,"alternative-id":["S0306452224006043"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2024.11.022","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semaglutide promotes the transition of microglia from M1 to M2 type to reduce brain inflammation in APP\/PS1\/tau mice","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2024.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}